CSL Limited (ASX: CSL)
Analysts at UBS have retained their buy rating and lifted the price target on this biotherapeutics company’s shares to $346.00. This follows an FY 2020 result which was in line with expectations and positive guidance for the year ahead. Overall, it appears to see a decent risk/reward on offer with its shares at the current level. I would have to agree with UBS on this one and believe CSL is a great option for investors.
CSL Limited (ASX: CSL)Analysts at UBS have retained their buy...
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$292.08 |
Change
-0.520(0.18%) |
Mkt cap ! $141.1B | |||
| Open | High | Low | Value | Volume |
| $290.71 | $293.00 | $290.55 | $125.8M | 431.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $292.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $292.10 | 712 | 3 |
View Market Depth
| Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |